Novartis Selects GSK’s Saynor As Next Sandoz CEO
Executive Summary
GlaxoSmithKline’s established products head, Richard Saynor, will return to Sandoz later this year to lead the Novartis division.
You may also be interested in...
Saynor Seeks To Take Sandoz Back To Basics
In an exclusive interview with Generics Bulletin, Sandoz’ CEO Richard Saynor explains how he wants the Novartis division to focus on the industry basics of being first-to-market with cost-competitive generics and biosimilars.
Sandoz Breaks Off Digital Deal With Pear
Sandoz has announced that partner Pear Therapeutics will now market alone the reSET and reSET-O digital therapeutics launched by the pair in the US almost a year ago. The move follows Richard Saynor taking charge of Sandoz as part of the Novartis unit’s current transformation.
Novartis Sees Space For Sandoz But In A Slimmer Streamlined Form
Sandoz has a place within Novartis as a more autonomous unit, the Swiss group’s CEO Vas Narasimhan says. But the generics and biosimilars division will have to sharpen up, aided by a 7% workforce cut.